AI-generated summary
This study protocol describes a planned randomized controlled trial of a night-time eye mask that emits dim green light, aimed at whether it can prevent progression of early age-related macular degeneration. The authors report that 60 participants with early AMD in one eye and neovascular AMD in the other will be randomized to the mask or an untreated control group for 12 months. The abstract reports no results, so no finding about effectiveness or safety is available.
- Who or what was studied
- Adults aged 55 to 88 years with early AMD in one eye and neovascular AMD in the fellow eye, recruited from neovascular AMD clinics, plus an additional 40 participants with healthy retinal appearance or early AMD only for baseline analysis.
- Limits stated in the abstract
- This is a study protocol with no outcome results reported, and the abstract describes the mask as a CE-marked device used for an off-label indication.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Age-related macular degeneration (AMD) is the leading cause of blindness among older adults in the developed world. The only treatments currently available, such as ranibizumab injections, are for neovascular AMD, which accounts for only 10 to 15% of people with the condition. Hypoxia has been implicated as one of the primary causes of AMD, and is most acute at night when the retina is most metabolically active. By increasing light levels at night, the metabolic requirements of the retina and hence the hypoxia will be considerably reduced. This trial seeks to determine whether wearing a light mask that emits a dim, green light during the night can prevent the progression of early AMD.
Methods/Design
ALight is a Phase I/IIa, multicentre, randomized controlled trial. Sixty participants (55 to 88 years old) with early AMD in one eye and neovascular AMD (nAMD) in the fellow eye will be recruited from nAMD clinics. They will be randomized (in the ratio 1:1), either to receive the intervention or to be in the untreated control group, stratified according to risk of disease progression. An additional 40 participants with healthy retinal appearance, or early AMD only, will be recruited for a baseline cross-sectional analysis. The intervention is an eye mask that emits a dim green light to illuminate the retina through closed eyelids at night. This is designed to reduce the metabolic activity of the retina, thereby reducing the potential risk of hypoxia. Participants will wear the mask every night for 12 months. Ophthalmologists carrying out monthly assessments will be masked to the treatment group, but participants will be aware of their treatment group. The primary outcome measure is the proportion of people who show disease progression during the trial period in the eye with early AMD. A co-primary outcome measure is the rate of retinal adaptation. As this is a trial of a CE-marked device for an off-label indication, a further main aim of this trial is to assess safety of the mask in the cohort of participants with AMD.
Trial Registration
International Standard Randomised Controlled Trials Register: ISRCTN82148651.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Age-related macular degeneration, Randomized controlled trial, Retina, Primary outcome, Trial registration, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.